NCT00917449View on ClinicalTrials.gov

Prevention of Type 2 Diabetes Mellitus by L-Arginine in Patients With Metabolic Syndrome

PHASE3CompletedINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Metabolic SyndromeImpaired Glucose ToleranceInsulin ResistanceEndothelial Dysfunction
Interventions
DRUG

L-arginine

Oral L-arginine (3.2 gr bid)for 18 months

DRUG

Placebo

Oral Placebo BID for 18 months

Trial Locations (1)

20132

Scientific Institute San Raffaele, Milan

All Listed Sponsors
lead

IRCCS San Raffaele

OTHER

NCT00917449 - Prevention of Type 2 Diabetes Mellitus by L-Arginine in Patients With Metabolic Syndrome | Biotech Hunter | Biotech Hunter